Carelle Reparon-Schuijt | Medical Advisor IMF
Zilveren Kruis

Carelle Reparon-Schuijt is a dedicated and experienced medical advisor for hospital medicines at health insurance company Zilveren Kruis. With a strong background in healthcare and a passion for improving patient outcomes, Carelle brings a unique perspective to the orphan drug industry. Her expertise lies in strategic planning, advocacy, and fostering partnerships to drive innovation and access to orphan drugs. Carelle's collaborative approach and deep understanding of the complexities within the healthcare system make her a valuable asset in navigating the challenges faced by rare disease patients and stakeholders. She is committed to driving positive change in the orphan drug landscape, ensuring that patients receive the care and treatments they deserve within the set rules and regulations in the reimbursement system in the Netherlands. Carelle's participation at the World Orphan Drug Congress 2025 is a testament to her commitment to advancing the field and shaping the future of orphan drug development and access.